EP 2023923 A2 20090218 - USE OF IXABEPILONE IN COMBINATION WITH CYP3A4 INHIBITORS FOR PHARMACEUTICALS
Title (en)
USE OF IXABEPILONE IN COMBINATION WITH CYP3A4 INHIBITORS FOR PHARMACEUTICALS
Title (de)
VERWENDUNG VON IXABEPILON IN KOMBINATION MIT CYP3A4-HEMMERN FÜR ARZNEIMITTEL
Title (fr)
UTILISATION DE L'IXABÉPILONE EN COMBINAISON AVEC DES INHIBITEURS DU CYP3A4 EN TANT QUE PRODUITS PHARMACEUTIQUES
Publication
Application
Priority
- US 2007069741 W 20070525
- US 80319306 P 20060525
Abstract (en)
[origin: WO2007140299A2] Disclosed are Uses of ixabepilone in combination with CYP3A4 inhibitors such as ketoconazole and lapatinib to achieve a surprisingly enhanced pharmacological effect as compared with when ixabepilone is administered unaccompanied by the CYP3A4 inhibitor. Also disclosed are methods of treating cancer in a human patient comprising administering to the human a therapeutically-effective combination of an amount of a the CYP3A4 inhibitor and an amount of ixabepilone to achieve the enhanced pharmacological effect.
IPC 8 full level
A61K 31/427 (2006.01); A61K 31/496 (2006.01); A61K 31/517 (2006.01); A61K 35/00 (2006.01); A61K 45/06 (2006.01)
CPC (source: EP)
A61K 31/427 (2013.01); A61K 31/496 (2013.01); A61K 31/517 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2017.12)
Citation (search report)
See references of WO 2007140299A2
Citation (examination)
CLINICAL TRIALS: "View of NCT00096317 on 2005_06_23", 23 June 2005 (2005-06-23), Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00096317/2005_06_23> [retrieved on 20110420]
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
WO 2007140299 A2 20071206; WO 2007140299 A3 20080703; EP 2023923 A2 20090218
DOCDB simple family (application)
US 2007069741 W 20070525; EP 07784137 A 20070525